Shire plc, the global specialty biopharmaceutical company, has signed an agreement with UCB to acquire the worldwide rights to Equasym IR and XL (methylphenidate hydrochloride) (excluding the USA, Canada and Barbados) used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
The details can be read here.
No comments:
Post a Comment